Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy

Clinical and Experimental Rheumatology

Volumn 33, Issue 3, 2015, Pages 375-384

  Doria, Andrea ^a   Iaccarino, Luca ^a   La Montagna, Giovanni ^b   Mathieu, Alessandro ^c   Piga, Matteo ^c   Galeazzi, Mauro ^d   Iuliano, Annamaria ^d   Maurel, Frédérique B ^e   Garofano, Anna M ^e   Perna, Alessandra G ^f   Porcasi, Rolando E ^g  

^a UNIVERSITY OF PADOVA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e IQVIA   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

^g GSK   (Italy)

Author keywords

Biologics; Clinical manifestations; Costs; Flares; Health resources; Hospitalisation; Immunosuppressants; SLE; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SELENA SLEDAI SCORE; SLICC ACR INDEX SCORE; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; AMBULATORY CARE; BLOOD; CLINICAL TRIAL; ECONOMICS; EMERGENCY HEALTH SERVICE; HOSPITAL COST; HOSPITALIZATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RECURRENT DISEASE; REMISSION; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AMBULATORY CARE; AUTOANTIBODIES; BIOMARKERS; DRUG COSTS; EMERGENCY MEDICAL SERVICES; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITALY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OFFICE VISITS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939552296     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. RUIZ-IRASTORZA G, KHAMASHTA MA, CASTELLINO G et al.: Systemic lupus erythematosus. Lancet 2001; 357: 1027-32.
2. DORIA A, ZEN M, CANOVA M et al.: SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010; 10: 55-60.
3. LOPEZ P, MOZO L, GUTIERREZ C et al.: Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus 2003; 12: 860-5.
4. PIETTE JC, PAPO T, AMOURA Z et al.: Lupus érythémateux Systémique Traité de Médecine. Paris, 2004.
5. NIGHTINGALE AL, FARMER RD, de VRIES CS: Systemic lupus erythematosus prevalence in the U.K.: methodological issues when using the General Practice Research Database to estimate frequency of chronic relapsing-remitting disease. Pharmacoepidemiol Drug Saf 2007; 16: 144-51.
6. GOVONI M, CASTELLINO G, BOSI S et al.: Incidence and prevalence of systemic lupus erythematosus in a district of North Italy. Lupus 2006; 15: 110-3.
7. BERTSIAS GK, IOANNIDIS JP, ARINGER M et al.: EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010; 69: 2074-82.
8. MOSCA M, TANI C, ARINGER M et al.: European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010; 69: 1269-74.
9. GATTO M, KISS E, NAPARSTEK Y, DORIA A: In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Med 2014; 12: 30.
10. van VOLLENHOVEN RF: Rituximab-Shadow, illusion or light?. Autoimmun Rev 2012; 11: 563-7.
11. BELIMUMAB: Summary of product characteristics. 2012 (accessed January 2012). Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002015/human_med_001466.jsp&mid=WC0b01ac058001d124.
12. SUTCLIFFE N, CLARKE AE, TAYLOR R et al.: Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40: 37-47.
13. HUSCHER D, MERKESDAL S, THIELE K et al.: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006; 65: 1175-83.
14. KHAMASHTA M, BRUCE I, GORDON C et al.: The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease. Lupus 2014; 23: 273-83.
15. SLAWSKY KA, FERNANDES AW, FUSFELD L et al.: A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res (Hoboken). 2011; 63: 1224-32.
16. DORIA A, AMOURA Z, CERVERA R et al.: Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis 2014; 73: 154-60.
17. BOMBARDIERI C, GLADMAN DD, UROWITZ MB et al.: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
18. GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al.: The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000; 27: 373-6.
19. PETRI M, KIM MY, KALUNIAN KC et al.: Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. N Engl J Med 2005; 353: 2550-8.
20. CERVERA R, DORIA A, AMOURA Z et al.: Patterns of systemic lupus erythematosus expression in Europe. Autoimmunity Rev 2014; 13: 621-9.
21. SUTTON EJ, DAVIDSO JE, BRUCE IN: The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review. Semin Arthritis Rheum 2013; 43: 352-61.
22. SCHWARTZMAN-MORRIS J, PUTTERMAN C: Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin Dev Immunol 2012; 2012: 604892.
23. KAMPHUIS S, SILVERMAN ED: Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010; 6: 538-46.
24. ALARCON GS, FRIEDMAN AW, STRAATON KV et al.: Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture, Lupus 1999; 8: 197-209.
25. IACCARINO L, ARIENTI S, RAMPUDDA M et al.: Mycophenolate mofetil in lupus glomerulonephritis: effectiveness and tolerability. Ann N Y Acad Sci 2007; 1110: 516-24.
26. IACCARINO L, RAMPUDDA M, CANOVA M et al.: Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases?. Autoimmun Rev 2007; 6: 190-5.
27. HAHN BH, McMAHON MA, WILKINSON A et al.: American college of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012; 64: 797-808.
28. BERTSIAS GK, TEKTONIDOU M, AMOURA Z et al.: Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82.
29. ORBACH H, ZANDMAN-GODDARD G, AMITAL H et al.: Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci 2007; 1109: 385-400.
30. AMITAL H, SZEKANECZ Z, SZUCS G et al.: Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?. Ann Rheum Dis 2010; 69: 1155-7.
31. AGMON-LEVIN N, BLANK M, ZANDMAN-GODDARD G et al.: Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011; 70: 145-50.
32. DORIA A, ARIENTI S, RAMPUDDA M et al.: Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 2008; 7: 192-7.
33. LAU CS, MAK A: The socioeconomic burden of SLE. Nat Rev Rheumatol 2009; 5: 400-4.
34. ZHU TY, TAM LS, LEE VW et al.: The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1159-67.
35. CARLS G, LI T, PANOPALIS P et al.: Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med 2009; 51: 66-79.
36. ZHU TY, TAM LS, LEE VW et al.: Systemic lupus erythematosus with neuropsychiatric manifestations incurs high direct costs: a cost-of-illness study in Hong Kong. Rheumatology (Oxford) 2009; 48: 564-8.
37. KOBELT G, BERG J, LINDGREN P et al.: Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006; 77: 918-26.
38. ZEN M, BASSI N, NALOTTO L et al.: Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol 2012; 30: 856-63.
39. DORIA A, IACCARINO L, GHIRARDELLO A et al.: Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 700-6.
40. DORIA A, GATTO M, ZEN M et al.: Optimiz-ing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmunity Rev 2014; 13: 770-7.